LEO Pharma Inc. US Revenue and Competitors

Madison, NJ USA

Location

$59.4B

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • LEO Pharma Inc. US's estimated annual revenue is currently $60.9M per year.(i)
  • 0
  • LEO Pharma Inc. US's total funding is $59.4B.

Employee Data

    00
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5M25-11%N/AN/A
#2
$35.8M1788%N/AN/A
#3
$5.4M27-25%N/AN/A
#4
$4180M145161%$550MN/A
#5
$12.5M6215%N/AN/A
#6
$6.7M119-37%$199.6MN/A
#7
$9.4M477%N/AN/A
#8
$10.3M516%N/AN/A
#9
$106.3M52916%N/AN/A
#10
$15.5M7720%N/AN/A
Add Company

What Is LEO Pharma Inc. US?

LEO Pharma Inc. -- the U.S. affiliate of LEO Pharma A/S -- opened its doors in the United States in 2009 and maintains its national headquarters in Madison, New Jersey. For more information, visit www.leo-pharma.us. Founded in 1908 and owned by the LEO Foundation, the healthcare company has devoted decades of research and development to delivering products and solutions to people with skin conditions. We are a company united by strong values passion, customer focus, innovation, adaptability and integrity. Our values reflect the way we strive to improve the quality of life for patients with skin diseases and these values are at the heart of our company's success and growth. LEO Pharma's global headquarters is located in Denmark and our global team consisting of approximately 5,000 people in 61 countries worldwide is LEO Pharma's greatest asset. With an incredible mix of people from different cultures and backgrounds, LEO Pharma is a workplace where passion and innovation thrive and people grow. The site is intended for discussions about LEO Pharma Inc. and our various initiatives. Discussions about pharmaceutical products are not permitted on this site. All content must be factual and non-promotional. LEO Pharma Inc. reserves the right to moderate or remove any content that may be inconsistent with legislation, industry ethics and regulations and LEO Pharma's values, including: - profane or vulgar language - insulting or offensive comments, such as displays of racism, calls to violence, hate propaganda, etc. - commercial or political advertising - copyright infringements, or any violation of the rights of external parties - automatically-generated content i.e. spam - wrong/false statements

keywords:N/A

$59.4B

Total Funding

N/A

Number of Employees

$60.9M

Revenue (est)

N/A

Employee Growth %

N/A

Valuation

N/A

Accelerator

LEO Pharma Inc. US News

2022-04-17 - Actinic Keratosis Treatment Market Top Key Company Profiles ...

... Top Key Company Profiles – Sun Pharmaceutical Ltd., Leo Pharma Inc. etc., ... majorly driven by that in the U.S. and European countries,...

2022-04-17 - Actinic Keratosis Treatment Market Size, Scope And Forecast ...

... 3M, Sun Pharmaceutical Industries Ltd., Gal derma S.A, Leo Pharma, ... New Jersey, United States – The Actinic Keratosis Treatment...

2022-04-06 - LEO Pharma Presents New Interim Long-Term Efficacy Data ...

“LEO Pharma is pleased that the ECZTEND trial findings continue to ... M.D., Vice President, U.S. Medical Affairs, LEO Pharma Inc. “We...

2016-01-28 - LEO Pharma launches new innovation lab with $65M in funding for non-pharmaceutical dermatology expansion

Catalina Cernica, Head of Innovation Lab UK said in a statement: “With LEO Innovation Lab, the company is doubling down on innovating in beyond the pill products and services. We’re a separate unit with an agile approach and the mindset of a lean startup. We can build and iterate solutions at s ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$11.9M0N/A$1.2M
#2
$1.1M0N/A$45.4M
#3
$10.3M0N/A$25.5M
#4
$0.1M1-50%N/A
#5
$0.1M10%N/A